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Abstract
Introduction: Several authors have underscored a strong relation between the molecular subtypes and the axillary status of
breast cancer patients. The aim of our work was to decipher the interaction between this classification and the probability of
a positive sentinel node biopsy.
Materials and Methods: Our dataset consisted of a total number of 2654 early-stage breast cancer patients. Patients treated
at first by conservative breast surgery plus sentinel node biopsies were selected. A multivariate logistic regression model
was trained and validated. Interaction covariate between ER and HER2 markers was a forced input of this model. The
performance of the multivariate model in the training and the two validation sets was analyzed in terms of discrimination
and calibration. Probability of axillary metastasis was detailed for each molecular subtype.
Results: The interaction covariate between ER and HER2 status was a stronger predictor (p=0.0031) of positive sentinel
node biopsy than the ER status by itself (p=0.016). A multivariate model to determine the probability of sentinel node
positivity was defined with the following variables; tumour size, lympho-vascular invasion, molecular subtypes and age at
diagnosis. This model showed similar results in terms of discrimination (AUC=0.72/0.73/0.72) and calibration (HL p=0.28/
0.05/0.11) in the training and validation sets. The interaction between molecular subtypes, tumour size and sentinel nodes
status was approximated.
Discussion: We showed that biologically-driven analyses are able to build new models with higher performance in terms of
breast cancer axillary status prediction. The molecular subtype classification strongly interacts with the axillary and distant
metastasis process.
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Introduction
Gene expression profiling of invasive breast carcinoma has
resulted in highlighting three main categories of breast cancer with
very specific features [luminal-like, basal-like, HER2-like][1].
Wirapati et al [2] showed that three main vectors-genes [ESR1,
HER2 and STK6, a marker of proliferation] are the biological
backbone of this classification. Although the methodology to
determine the molecular subtypes has still to be improved[3],
many publications have validated this classification [2][4]. It has
been shown that the molecular subtypes differ in their response to
neaoadjuvant systemic treatment [5], loco-regional recurrence [6],
metastasis pattern [7,8], time to metastasis and overall survival [3].
Furthermore, several authors have underscored a strong relation
between the molecular subtypes classification and the axillary
status of breast cancer patients [9–16]. As the nodal status is the
most robust and the strongest factor correlated to overall survival
in breast cancer patients, and is one of the major determinants in
therapeutic decisions, axillary staging (either by sentinel node
biopsy or axillary lymph node dissection) is a mandatory step in
breast cancer management. Many predictors of axillary lymph
nodes metastases have been previously published. Tumour size,
tumour grade, tumour location, presence of lymphatic/vascular
invasion, high MIB-1 index, age at diagnosis, S phase, estrogen
receptor status (ER), progesteron receptor status (PR), HER2 status
are independent variables identified in these studies [17–25].
The aim of our work was to decipher the relation between the
molecular subtype classification as defined by a combination of ER
and HER2 status evaluated by immuno-histochemistry (IHC) and
confirmed by FISH in case of IHC-HER2 2+ and the probability of
a positive sentinel node biopsy. Using one training set and two
validation sets we showed a benefit to introduce the ER and HER2
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20297biomarkers interaction covariate to identify, before surgery, a
patient with a high risk of axillary metastasis. Furthermore we
showed for each molecular subtype a very specific correlation
pattern between the tumour size and the probability of a positive
sentinel node biopsy. We hypothesized from these results that the
axillary lymph node metastasis process is predominantly correlated
to intrinsic biological properties in the ER negative HER2 negative
breast cancer subgroup whereas stochastic events, tumour size,
Table 1. Clinical and pathological features of the training set
and two validation sets.
Training set
Number(%)
Validation
set 1
Number(%)
Validation
set 2
Number(%)
Chi
2 p
value
All patients 1543 (100) 615 (100) 496 (100)
Age (years)
,60 973 (63.1) 330 (53.7) 296 (59.7) 1e-04
60–65 218 (14.1) 90 (14.6) 60 (12.1)
.65 352 (22.8) 195 (31.7) 140 (28.2)
ER (IHC)
Positive 1343 (87) 557 (90.6) 458 (92.3) 0.0015
Negative 200 (13) 58 (9.4) 38 (7.7)
HER2 (IHC-FISH)
Positive 132 (8.6) 47 (7.6) 125 (25.2) ,0.0001
Negative 1411 (91.4) 568 (92.4) 371 (74.8)
ER HER2(IHC
-FISH)
ERneg HER2neg 147 (9.5) 40 (6.5) 24 (4.8)
ERpos HER2neg 1264 (81.9) 528 (85.9) 347 (70) ,0.001
ERpos HER2pos 79 (5.1) 29 (4.7) 109 (22)
ERneg HER2pos 53 (3.4) 18 (2.9) 16 (3.2)
Tumour size
(mm)
#20 1333 (87.7) 560 (91.2) 440 (88.7) NS
.20 187 (12.3) 54 (8.8) 56 (11.3)
Histological
Grade
1 507 (33.1) 198 (32.4) 236 (47.6) ,0.0001
2 707 (46.1) 294 (48) 191 (38.5)
3 318 (20.8) 120 (19.6) 67 (13.5)
Mitotic index
1 1048 (68.9) 437 (71.3) 344 (69.3) NS
2 237 (15.6) 89 (14.5) 79 (15.7)
3 235 (15.5) 87 (14.2) 62 (12.5)
LVI
Negative 1164 (76.4) 502 (81.6) 386 (77.8) 0.0301
Positive 360 (23.6) 113 (18.4) 110 (22.2)
Subtype
Ductal 1293 (83.8) 520 (84.6) 425 (85.7) 0.0037
Lobular 203 (13.2) 80 (13) 71 (14.3)
Other(s) 47 (3) 15 (2.4)
No SN removed
1 416 (27) 126 (20.5) 153 (30.8) 1e-04
2–3 790 (51.2) 299 (48.6) 269 (54.2)
.3 337 (21.8) 190 (30.9) 74 (15)
No of positive
SN Biopsy
Positive 516 (33.4) 152 (24.7) 135 (27.2) 1e-04
Negative 1027 (66.6) 463 (75.3) 361 (72.8)
LVI: Lymphovascular Invasion. SN: Sentinel Node. No:Number. IHC: Immuno-
Histochemistry. FISH: Fluorescent In Situ Hybridization.
doi:10.1371/journal.pone.0020297.t001
Table 2. Clinical and pathological features of the sentinel
node negative and positive tumours.
Training Set
Negative SNs
Number(%)
Positive SNs
Number(%)
Chi
2
pvalue
All patients 1027 (100) 516 (100)
Age (years)
,60 608 (62.5) 365 (37.5)
60–65 150 (68.8) 68 (31.2) p,0.0001
.65 269 (76.4) 83 (23.6)
ER (IHC)
Positive 879 (65.5) 464 (34.5) p=0.0168
Negative 148 (74) 52 (26)
HER2 (IHC-FISH)
Positive 85 (64.4) 47 (35.6) p=0.58
Negative 942 (64.7) 469 (33.3)
ER HER2(IHC-FISH)
ERneg HER2neg 117 (79.6) 30 (20.4)
ERpos HER2neg 825 (65.3) 439 (34.7) p=0.0031
ERpos HER2pos 54 (68.4) 25 (31.6)
ERneg HER2pos 31 (58.5) 22 (41.5)
Tumour size (mm)
#20 938 (70.4) 395 (29.6) p,0.0001
.20 70 (37.4) 117 (62.6)
Histological Grade
1 363 (71.6) 144 (28.4)
2 447 (63.2) 260 (36.8) p=0.0083
3 207 (65.1) 111 (34.9)
Mitotic index
1 719 (68.6) 329 (31.4)
2 140 (59.1) 97 (40.9) p=0.013
3 150 (63.8) 85 (36.2)
LVI
Negative 851 (73.1) 313 (26.9) p,0.0001
Positive 160 (44.4) 200 (55.6)
Subtype
Ductal 847 (65.5) 446 (34.5)
Lobular 143 (70.4) 60 (29.6) p=0.076
Other(s) 37 (78.7) 10 (21.3)
No SN removed
1 287 (27.3) 129 (31)
2–3 470 (45.7) 320 (40.5) p,0.0001
.3 270 (26) 67 (19.9)
LVI: Lymphovascular Invasion. SN: Sentinel Node. No:Number. IHC: Immuno-
Histochemistry. FISH: Fluorescent In Situ Hybridization.
doi:10.1371/journal.pone.0020297.t002
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nants in the ER positive or HER2 positive breast cancer subgroups.
Materials and Methods
Patients
Our dataset consisted of one training set of 1543 early-stage
breast cancer patients treated between 2000 and 2007 and a
validation set of 615 early-stage breast cancer patients treated in
2008 and identified through the Institut Curie prospective breast
cancer database. A second external validation set consisted of 496
early-stage breast cancer patients treated between 2001 and 2007
and identified through the Hopital Tenon, department of
gynecology, prospective breast cancer database. The main
inclusion criterion were patients with an infiltrating breast
carcinoma ,30 mm based on clinical and radiological features,
Table 3. Multivariate logistic regression model to predict the probability of axillary metastases.
Training Set. Institut Curie Validation Set. Institut Curie Validation Set. Tenon Hospital
N OR CI pvalue N OR CI pvalue N OR CI pvalue
Tumor Size mm 1543 1.08 1.O6/1.1 ,0.00001 615 1.07 1.04/1.1 ,0.00001 496 1.04 1.01/1.06 0.005
LVI No 1164 1 502 1 386 1
Yes 360 2.69 2/3.5 ,0.00001 113 4.14 2.6/6.6 ,0.00001 110 5.2 3.2/8.5 ,0.00001
Molecular
Subtypes
ERneg
HER2neg
147 1 40 1 24 1
ERneg
HER2pos
53 2.95 1.4/6.3 0.005 18 3.8 0.9/16 0.07 16 12.5 1.6/95 0.01
ERpos
HER2neg
1264 2.9 1.8/4.6 0.00001 528 2.4 0.9/6.6 0.08 347 9.3 1.6/51.9 0.01
ERpos
HER2pos
79 1.8 0.9/3.5 0.08 29 2 0.55/7.8 0.27 109 8.2 1.4/47.4 0.02
Age ,=60
(years)
973 1 330 1 296 1
]60–65] 218 0.78 0.5/1.1 0.16 90 0.77 0.4/1.4 0.4 60 1.3 0.7/2.5 0.32
.65 352 0.56 0.4/0.7 0.0001 195 0.6 0.4/1.03 0.06 140 0.6 0.3/0.9 0.04
LVI: Lymphovascular Invasion. ERneg: Estrogen Receptor Negative. ERpos: Estrogen Receptor Positive. HER2neg: HER2 negative. Her2pos: HER2 positive. OR: Odds Ratio.
CI: Confidence Interval. N: Number of patients
doi:10.1371/journal.pone.0020297.t003
Figure 1. Receiver Operating Curves and Discrimination Curves. A) Receiver Operating Curves. Blue; Institut Curie Training Set. Orange;
Institut Curie Validation Set. Red; Hopital Tenon Validation Set. Se; Sensitivoty. Spe; Specificity. B) Discrimination Curves. Blue; Institut Curie Training
Set. Orange; Institut Curie Validation Set. Red; Hopital Tenon Validation Set.
doi:10.1371/journal.pone.0020297.g001
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conservative surgery plus a sentinel node (SN) biopsy. The
procedure was performed with blue patent, radioisotope or a
combination, as previously described, in line with French
recommendations. SN biopsy was performed as previously
described [26]. Axillary lymph node dissection was performed
during the same procedure when the SN was positive by imprint
cytology or frozen section. A second operation was performed
when either hematoxylin-eosin staining or immunohistochemistry
revealed tumor cells in the SN postoperatively, including isolated
tumour cells. Pathologic SN examination methods were as
reported previously [26]. Patients receiving a neoadjuvant
treatment (chemotherapy, hormone-therapy or radiotherapy) or
with a locoregional recurrence were systematically excluded from
the study. The clinical data (age at diagnosis, treatment protocols)
were extracted from the Institut Curie prospective breast cancer
database and from the Hospital Tenon, department of gynecology,
prospective breast cancer database.
Tumor samples
The following histological features were retrieved: tumour type,
tumour size, histological grade according to Elston and Ellis
grading system (Histopathology 1991), Mitotic Index, Lympho
Vascular Invasion, Estrogen Receptor status, Progesterone
Receptor status, HER2 status, number of positive sentinel nodes,
number of sentinel nodes. Mitotic Index (MI) corresponded to the
number of mitoses observed in 10 successive high power fields
(HPF) using a microscope with a 40x /0.7 objectives and a 10x
ocular, each. Mitotic Index was assessed on histological sections
stained by Hematein, Eosin and Saffron. The criteria of Van Diest
and al were used to define mitotic figures [27,28]. Estrogen
Receptor (ER) and Progesteron Receptor (PR) immunostainings
were determined as follow. After rehydration and antigenic
retrieval in citrate buffer (10 mM, pH 6.1), the tissue sections
were stained for estrogen receptor (clone 6F11, Novocastra, 1/
200), and progesterone receptor (clone 1A6, Novocastra, 1/200).
Revelation of staining was performed using the Vectastain Elite
ABC peroxidase mouse IgG kit (Vector Burlingame, CA) and
diaminobenzidine (Dako A/S, Glostrup, Denmark) as chromogen.
Positive and negative controls were included in each slide run.
Cases were considered positive for ER and PR according to
standardized guidelines using $10% of positive nuclei per
carcinomatous duct. The determination of HER2 over-expression
status was determined according to the American Society of
Clinical Oncology (ASCO) guidelines [29].
The SLN histopathological assessment protocol has been
published by Fre ´neaux et al [26]. SLN samples were serially
sectioned and stained with HE. Negative HE cases were then
analyzed by serial sectioning with IHC. Positive sentinel nodes
were classified into two groups according to the size of the
metastasis: macrometastasis (.2 mm) and micrometastasis
(,=2 mm) detected either by HE staining or by cytokeratin
IHC.
Figure 2. Nomogram to calculate the probability of sentinel node positivity in breast carcinoma. Nomogram to calculate the probability
of sentinel node positivity in breast carcinoma. First: identify for each of the 4 variables the corresponding Beta value. Second, calculate the sum of
the 4 Beta values. Third, report the Sum Beta Value to the Probability scale.
doi:10.1371/journal.pone.0020297.g002
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Baseline characteristics were compared between groups using
Chi-square or Fisher’s exact tests for categorical variables and
Student’s t-tests for continuous variables. To develop well-
calibrated and exportable nomograms for prediction of sentinel
node positivity, we built a multivariate logistic regression model
in a training cohort and validated it in two independent
validation cohorts. First, univariate logistic regression analysis
was performed to test the association of the sentinel lymph node
status to the following variables: patient age, tumor diameter,
histologic type of tumor, histological grade, lymphovascular
invasion, ER status, PR status, HER2 status. Interaction
covariate between ER and HER2 status were tested. The log-
linearity of the continuous variables was study by fitting a
polynomial functions with different degree or step functions in a
logistic model. Age at diagnosis was subdivided in 3 classes and
the tumour size was kept as a continuous variable. Second, a
multivariate logistic regression analysis was performed to
determine the probability of having a positive sentinel node
biopsy procedure and to build a nomogram. Significant variables
identified through univariate analysis were used as input in the
multivariate analysis. The multivariate model performance was
quantified with respect to discrimination and calibration.
Discrimination (i.e., whether the relative ranking of individual
predictions is in the correct order) was quantified with the area
under the receiver operating characteristic curve. Calibration
(i.e., agreement between observed outcome frequencies and
predicted probabilities) was studied with graphical representa-
tions of the relationship between the observed outcome
frequencies and the predicted probabilities (calibration curves):
the grouped proportions versus mean predicted probability in
groups defined by deciles and the logistic calibration were
represented. The calibration was tested using the Hosmer-
Lemeshow test. This test compares mean predicted probability
and observed proportions using a 8 degree of freedom chi-square
for the training set and a 9 degree of freedom chi-square for the
validation sets. The analyses were performed using R software
(http://cran.r-project.org).
A java web based interface is available at www.cancerdusein.
curie.fr
The study was approved by the breast cancer study group of the
Institut Curie.
Results
Table 1 summarizes the training (1543 patients) and the two
validation sets (615 and 496 patients). These three populations
significantly differ in terms of age at diagnosis, ER status, HER2
status, histological grade, lympho vascular invasion, histological
subtypes, number of sentinel nodes removed and number of
Figure 3. Percentage of positive sentinel node. Percentage of positive sentinel node calculated for each 5 mm tumour size subclasses from 0 to
40 mm. Number of patient by tumour size subclasses are printed. The training and two validation datasets have been merged to determine these
probability plots.
doi:10.1371/journal.pone.0020297.g003
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interest in a validation process to test the robustness of a
classification algorithm. The training set (Table 2) was composed
of 516 patients with a positive sentinel node biopsy (33.4%) and
1027 patients with a negative sentinel node biopsy (66.6%). We
showed that patients with a positive sentinel node biopsy differed
from those with a negative biopsy in terms of age at diagnosis, ER
status, pathological tumor size, histological grade, mitotic index,
lympho vascular invasion and number of sentinel node removed.
The proportion of patients with a positive HER2 status was not
significantly different between the two groups [8.6% vs 7.6%,
p=0.58]. The interaction covariate between ER and HER2 status
[ERneg HER2neg, ERpos HER2neg, ERpos HER2pos, ERneg
HER2pos] was a stronger predictor (p=0.0031) of positive
sentinel node biopsy than the ER status by itself (p=0.016). We
designed a multivariate logistic regression model to determine the
probability of having a positive sentinel node biopsy (Table 3). The
initial input was based on the variables found significant in the
univariate analysis. Tumour size, lympho-vascular invasion,
molecular subtypes classification as defined by the interaction
covariate between the ER and HER2 status and age at diagnosis
were the final input into this model. Odds Ratio, Confidence
Intervals and pvalue are summarized in table 3. The logistic
regression parameters indicate the relative degree to which each of
these variables is correlated to nodal metastasis. The performance
of the multivariate model in the training and the two validation
sets was analyzed in terms of discrimination and calibration. ROC
curves are plotted in figure 1a. It showed a very similar area under
curves (AUC) for each population [Training set AUC=0.72 (95%
CI, 0.69–0.75), IC validation set AUC=0.73 (95% CI, 0.68–0.78),
T validation set AUC=0.72 (95% CI, 0.67–0.77)]. Calibration
curves are plotted in figure 1b. The logistic model was well
calibrated, with no significant difference between the predicted
and the observed probability in the training and the two validation
sets. The Hosmer-Lemeshow goodness of fit statistic showed
similar results when applied to each datasets (Institut Curie
Trainin Set p=0.28, Institut Curie Validation Set p=0.05,
Hopital Tenon Validation Set p=0.11). Using the multivariate
logistic regression model, a nomogram was build (Figure 2). Finally
we analyzed the correlation between the tumour size and the
Table 4. Number and percentage of lymph node negative breast cancer patients by molecular subgroup as determined by a
combination of ER and HER2 IHC markers. Review of literature.
References Molecular Subtypes ER status
ER- HER2-LNN/LN
(%)
ER+ HER2-LNN/LN
(%)
ER- HER2+LNN/LN
(%)
ER+ HER2+LNN/LN
(%)
Liu et al [11] 237/477 (49.6) 68/149 (45.6) HR negative samples
Lu et al [9] 27/38 (71) 25/60 (41.6) 6/15 (40) 6/16 (37.5) Threshold 10%
Kim et al [14] 118/237 (49.7) 171/345 (49.6) 61/133 (45.9) 23/61 (37.7) Threshold 10%
Nguyen et al [15] 59/89 (66) 440/595 (74) 16/32 (50) 49/77 (64) Threshold 1%
Crabb et al [10] 199/315 (63.3) 1397/2397 (58.5) 109/240 (32) 95/210 (45.2) Threshold 1%
Van Calster et al [12] 126/193 (65.3) 1139/1778 (64) 56/88 (63.6) 83/168 (49.4) Any positive nuclear staining
Lee et al [13] 33/58 (56.8) 143/189 (75.6) 27/41 (65.8) 38/54 (70.4) Threshold 10%
Voduc et al [16] 350/556 (62.9) 1154/2017 (57.2) 102/227 (44.9) 85/185 (45.9) ER positive status. Threshold 1%
LNN; Nulber of Lymph Node Negative Patients. LN; Number of patients.
doi:10.1371/journal.pone.0020297.t004
Table 5. Percentage and Confidence Interval of positive sentinel node calculated for each 5 mm tumour size subclasses from 0 to
40 mm.
Molecular
Subtypes ERneg HER2neg ERneg HER2pos ERpos HER2pos ERpos HER2neg
Tumour Size
(mm) SNpos/SN % CI SNpos/SN % CI SNpos/SN % CI SNpos/SN % CI
]0,5] 0/13 0 (0–24) 3/8 35.5 (8–75) 1/12 8.3 (0.2–38) 7/106 6.6 (3–13)
]5,10] 4/35 11.4 (3–26) 4/20 20 (5–43) 9/37 24.3 (12–41) 138/677 20.4 (17–23)
]10,15] 9/59 15.2 (7–27) 9/26 34.6 (17–55) 24/91 26.3 (17–36) 221/726 30.4 (27–33)
]15,20] 11/60 18.3 (9–30) 9/18 50 (26–74) 16/46 34.7 (21–50) 155/375 41.3 (36–46)
]20,25] 7/27 25.9 (11–46) 7/8 87.5 (47–99) 7/13 53.8 (25–80) 73/122 59.8 (50–68)
]25,30] 1/5 20 (0.5–71) 2/2 100 (16–100) 7/9 77.7 (40–97) 22/38 57.9 (40–73)
]30,35] 1/1 100 (2.5–100) NA NA 2/3 66.6 (9–99) 11/19 57.9 (33–79)
]35,40] 2/2 100 (15–100) 1/1 100 (25–100) 2/2 100 (15–100) 12/16 75 (29–96)
ERneg; ER negative status. ERpos; ER positive status. HER2neg; HER2 negative status. HER2pos; HER2 positive status. SNpos; number of positive sentinel node. SN;
number of sentinel node retrieved.
doi:10.1371/journal.pone.0020297.t005
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each molecular subtype (Figure 3, Table 4). We showed an almost
null slope of the correlation axis in the ER negative HER2
negative subgroup. The probability of having an axillary
metastasis seemed to be more or less 20% whatever the tumour
size. Both ER positive (either HER2 negative or positive) tumour
subgoups showed an intermediate slope and the ER negative
HER2 positive tumour subgroup showed the steepest slope.
Tumour size was a major determinant of axillary metastasis
development only in the HER2 positive or ER positive tumour
subgroups. Sentinel node biopsies for breast cancers of less than
30 mm was associated with a rate of less than 30% of axillary
metastasis in the ER negative HER2 negative subgroup and with
one higher than 50% in the other three subgroups. For each
molecular subtype as defined by a combination of ER and HER2
immuno-histochemistry markers, we summarized (table 5) eight
publications addressing the percentage of axillary metastases [9–
16].
Discussion
The aim of our work was to decipher the relation between the
molecular subtype classification as defined by a combination of ER
and HER2 status and the probability of a positive sentinel node
biopsy. Using one training set and two validation sets we showed a
benefit to introduce the ER and HER2 biomarkers interaction
covariate to identify, before surgery, a patient with a high risk of
axillary metastasis. Using tumour size, lympho-vascular invasion,
molecular subtypes classification and age at diagnosis, we designed
a robust multivariate logistic regression model to determine the
probability of having a positive sentinel node biopsy. We validated
this model in two independent and very different datasets and
showed a very similar performance in terms of calibration and
discrimination. Lu et al identified a similar multivariate model to
predict lymph node metastases that included tumour size, lympho
vascular invasion and tumour subtypes defined by a combination
of ER status, HER2 status and modified Bloom and Richardson
grade [9]. Furthermore we identified for each molecular subtype a
very specific correlation pattern between the tumour size and the
probability of a positive sentinel node biopsy. The ER negative
HER2 negative breast cancer subgroup nodal status was almost
independent from the tumour size with a relative constant trend of
axillary metastases around 20%. Conversely the ER positive or
HER2 positive breast cancer subgroups showed a strong and
almost linear correlation between the tumour size and the
percentage of axillary metastasis.
Tumour size and lympho vascular invasion are the main
predictors of axillary metastases identified in many studies [17–
25]. However tumour size and lympho vascular invasion have
never been robustly related to any pathological or biological
marker. High throughput gene expression profiles analysis failed to
identify a set of genes correlated to the nodal status, the tumour
size or the lympho vascular invasion [9]. The gene expression
profile of paired primary tumour and corresponding axillary
metastases have previously been shown as very similar [30]. From
these observations, conclusions have been drawn that growth rate,
time and stochastic factors seem to be the main determinants of
the nodal status. However, several authors have recently
underscored a significant relation between the molecular subtypes
classification and the axillary status of breast cancer patients [9–
16]. These evidences sustained the idea that nodal status is still a
potential signature of the intrinsic biological properties of a
primary tumour. Perou et al have identified the molecular subtype
classification in the late 909 and it was a major breakthrough in the
breast cancer research process [1]. This classification underscored
the great heterogeneity of breast cancer. It is now a common
knowledge that the pathologic characteristics, the aCGH profiles,
the gene and miRNA expression profiles and altered pathways are
dramatically different between these categories and sustained an
overview of breast cancer as a disease composed of very different
and independent molecular subgroups.
For each molecular subtype as defined by a combination of ER
and HER2 immuno-histochemistry markers, we summarized
(table 5) eight publications addressing the percentage of axillary
metastases [9–16]. As reported in our study the ER negative HER2
negative tumour subgroup has the lowest rate of axillary metastasis
and the HER2 positive tumour one, the highest. We hypothesized
from the whole results that the axillary lymph node metastasis
process is predominantly related to intrinsic biological properties
in the ER negative HER2 negative breast cancer subgroup when
stochastic events, tumour size, growth rate and lympho vascular
invasion are the main determinants in both the ER positive or the
HER2 positive breast cancer subgroups. As the molecular subtypes
differ in terms of relapse free survival and overall survival [ER
negative HER2 negative and HER2 positive breast cancer patients
experience a shorter relapse free survival and overall survival] and
the nodal status is the strongest prognostic predictor, we
highlighted a very complex interaction network between the
primary tumour, the nodal status and the distant metastases. The
molecular subtype classification is one determinant of this network.
Finally we showed that biologically-driven analyses are able to
build new models with higher performance in terms of breast
cancer axillary status prediction. The molecular subtype classifi-
cation is the first stratification level of breast carcinoma and
strongly interacts with the axillary and distant metastasis process.
Large integrative analyses have to be performed to explain why
ER negative HER negative tumours have a low rate of axillary
metastasis and a high rate of distant metastases. Conversely HER2
positive tumours have a rate of axillary metastases strongly related
to the tumour size and a high rate of distant metastases.
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